Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Korea Otsuka Pharmaceutical Co.,Ltd. |
---|---|
Information provided by: | Korea Otsuka Pharmaceutical Co.,Ltd. |
ClinicalTrials.gov Identifier: | NCT00576706 |
To prove that the efficacy and safety of Mucosta® (Rebamipide) is non-inferior to those of Cytotec® (Misoprostol), in terms of prevention of NSAID-induced gastric ulcer.
Condition | Intervention | Phase |
---|---|---|
Rheumatoid Arthritis Osteoarthritis Ankylosing Spondylitis |
Drug: Rebamipide Drug: Misoprostol |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase III, Randomized, Double-Dummy, Double Blind, Misoprostol-Comparative Clinical Trial to Evaluate the Efficacy and Safety of Mucosta® Tablet in the Prevention of NSAID-Induced Gastrointestinal Complications |
Estimated Enrollment: | 396 |
Study Start Date: | December 2007 |
Estimated Study Completion Date: | December 2008 |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: Rebamipide
Rebamipide 100㎎, 12 weeks
|
2: Active Comparator |
Drug: Misoprostol
Misoprostol 200㎍ 12 weeks
|
Ages Eligible for Study: | 19 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Geumbo Lee | 822-3465-5496 | gb122@otsuka.co.kr |
Korea, Republic of | |
Recruiting | |
Daegu, Korea, Republic of | |
Recruiting | |
Seoul, Korea, Republic of | |
Recruiting | |
Suwon, Korea, Republic of | |
Recruiting | |
Chonju, Korea, Republic of | |
Recruiting | |
Pusan, Korea, Republic of | |
Recruiting | |
Gwangju, Korea, Republic of | |
Recruiting | |
Daejeon, Korea, Republic of |
Principal Investigator: | Soo-Heon Park, MD PhD | Catholic University Hospital |
Responsible Party: | Korea Otsuka Pharmaceutical Co.,Ltd. ( Korea Otsuka Pharmaceutical Co.,Ltd. ) |
Study ID Numbers: | 037-KOA-0701i |
Study First Received: | December 17, 2007 |
Last Updated: | July 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00576706 |
Health Authority: | Korea: Food and Drug Administration |
Patients with rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis or any other arthritis-like disease requiring continuous NSAIDs therapy |
Spinal Diseases Autoimmune Diseases Osteoarthritis Spondylarthropathy Joint Diseases Misoprostol Arthritis, Rheumatoid Rheumatic Diseases Rebamipide |
Bone Diseases Musculoskeletal Diseases Arthritis Connective Tissue Diseases Spondylitis, Ankylosing Spondylarthritis Spondylitis Ankylosis Spondylarthropathies |
Antioxidants Immune System Diseases Molecular Mechanisms of Pharmacological Action Oxytocics Physiological Effects of Drugs Gastrointestinal Agents Enzyme Inhibitors Reproductive Control Agents |
Infection Abortifacient Agents, Nonsteroidal Protective Agents Pharmacologic Actions Bone Diseases, Infectious Therapeutic Uses Abortifacient Agents Anti-Ulcer Agents |